- Home
- OUST vs VERA Comparison
OUST vs VERA Comparison
Compare OUST & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OUST | VERA |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | OUST | VERA |
|---|---|---|
| Price | $23.32 | $48.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $34.80 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $137,298,000.00 | N/A |
| Revenue This Year | $35.72 | N/A |
| Revenue Next Year | $35.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.20 | N/A |
| 52 Week Low | $6.34 | $18.53 |
| 52 Week High | $41.65 | $56.05 |
Technical Indicators
Market Signals| Indicator | OUST | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 59.89 |
| Support Level | $21.04 | $47.22 |
| Resistance Level | $23.61 | $56.05 |
| Average True Range (ATR) | 1.36 | 2.51 |
| MACD | 0.10 | -0.69 |
| Stochastic Oscillator | 46.49 | 32.26 |
Price Performance
Historical ComparisonAbout OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.